cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
CD4+/CD56+ Hematodermic Neoplasm
Explore 34 assets in CD4+/CD56+ Hematodermic Neoplasm →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03326921CT.gov HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · CD4+/CD56+ Hematodermic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr (this asset) | Fred Hutchinson Cancer Center | P1 | CC · 43 |
| Tagraxofusp | French Innovative Leukemia Organisation | P2 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Venetoclax | French Innovative Leukemia Organisation | P2 | B |
| Rituximab | St. Jude Children's Research Hospital | P2 | B |
| Cytarabine | Therapeutic Advances in Childhood Leukemia Consortium | P2 | B |
| Dexasone | Therapeutic Advances in Childhood Leukemia Consortium | P2 | B |
| (+)-Vincristine | Therapeutic Advances in Childhood Leukemia Consortium | P2 | B |
+39 more in the CD4+/CD56+ Hematodermic Neoplasm cohort
Other indications for cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Biphenotypic Leukemia | — | P1 | CC · 43 |
| Acute Undifferentiated Leukemia | — | P1 | CC · 43 |
| Juvenile Myelomonocytic Leukemia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr in CD4+/CD56+ Hematodermic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd8-and-cd4-donor-memory-t-cells-expressing-ha1-specific-tcr-cd4cd56-hematodermic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →